Prosecution Insights
Last updated: April 19, 2026
Application No. 17/912,485

SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1

Non-Final OA §102
Filed
Sep 16, 2022
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Board Of Regents Of The University Of Texas System
OA Round
3 (Non-Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
2y 11m
To Grant
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
869 granted / 1225 resolved
+10.9% vs TC avg
Minimal +0% lift
Without
With
+0.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
43 currently pending
Career history
1268
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
14.6%
-25.4% vs TC avg
§102
29.8%
-10.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1225 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment 2. The amendments to the claims filed on January 13, 2026 have been fully considered. The amendments are sufficient to overcome the outstanding ground of rejection over RN2341169-68-2. 3. New grounds of rejection are set forth in this office action Claim Objections 4. Claims 4-9 objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 5. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 2286277-82-3 ( PNG media_image1.png 118 294 media_image1.png Greyscale ). The reference has a date of March 14, 2019 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R6=R8=R9=H; X=O; R4=phenyl; R7=chloro. 6. Claim(s) 2 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 1655511-65-1 ( PNG media_image2.png 138 314 media_image2.png Greyscale ). The reference has a date of March 15, 2015 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=OH; R2=R3=R5=R6=R8=R9=H; X=CH2; R4=phenyl; R7=NO2. 7. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 1647534-10-8 ( PNG media_image3.png 138 280 media_image3.png Greyscale ). The reference has a date of February 15, 2015 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R7=R8=H; R6=R9=Br; X=O; R4=phenyl. 8. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 868145-09-9 ( PNG media_image4.png 136 298 media_image4.png Greyscale ). The reference has a date of November 16, 2005 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R6=R8=H; R7=R9=Me; X=O; R4=phenyl. 9. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 867135-36-2 ( PNG media_image5.png 126 286 media_image5.png Greyscale ). The reference has a date of November 9, 2005 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R6=R8=R9=H; R7= Me; X=O; R4=phenyl. 10. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 857947-07-0 ( PNG media_image6.png 122 314 media_image6.png Greyscale ). The reference has a date of August 3, 2005 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R6=R8=R9=H; R7= amino; X=O; R4=phenyl. 11. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 835890-87-4 ( PNG media_image7.png 122 292 media_image7.png Greyscale ). The reference has a date of February 23, 2005 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R6=R8=R9=H; R7= Br; X=O; R4=phenyl. 12. Claim(s) 2 and 3 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 17811-72-2 ( PNG media_image8.png 132 266 media_image8.png Greyscale ). The reference has a date of November 16, 1984 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: R1=R2=R3=R5=R6=R7=R8=R9=H; X=O; R4=phenyl. 13. Claim(s) 10 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 713500-93-7 ( PNG media_image9.png 106 264 media_image9.png Greyscale ). The reference has a date of July 21, 2004 which antedates the present claims having a filing date of March 17, 2021 and priority claim to provisional application dated March 17, 2020. The compound corresponds to the present claims in the following manner: it corresponds to compound 9q. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Sep 16, 2022
Application Filed
Feb 24, 2025
Applicant Interview (Telephonic)
Feb 24, 2025
Examiner Interview Summary
May 05, 2025
Non-Final Rejection — §102
Jul 30, 2025
Response Filed
Oct 29, 2025
Final Rejection — §102
Dec 12, 2025
Response after Non-Final Action
Jan 05, 2026
Applicant Interview (Telephonic)
Jan 05, 2026
Examiner Interview Summary
Jan 12, 2026
Examiner Interview Summary
Jan 12, 2026
Applicant Interview (Telephonic)
Jan 13, 2026
Response after Non-Final Action
Feb 12, 2026
Applicant Interview (Telephonic)
Feb 23, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595251
AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS
2y 5m to grant Granted Apr 07, 2026
Patent 12594266
TRITERPENOID ANTIFUNGALS FOR THE TREATMENT OR PREVENTION OF PNEUMOCYSTIS SPP. PNEUMONIA
2y 5m to grant Granted Apr 07, 2026
Patent 12583854
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12583855
RET SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583821
SALT OF OMECAMTIV MECARBIL AND PROCESS FOR PREPARING SALT
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.4%)
2y 11m
Median Time to Grant
High
PTA Risk
Based on 1225 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month